27.75
-0.86(-3.01%)
Currency In USD
| Previous Close | 28.61 |
| Open | 29 |
| Day High | 29 |
| Day Low | 26.37 |
| 52-Week High | 130 |
| 52-Week Low | 6.76 |
| Volume | 1.1M |
| Average Volume | 1.43M |
| Market Cap | 243.25M |
| PE | 0.01 |
| EPS | 2,537 |
| Moving Average 50 Days | 39.68 |
| Moving Average 200 Days | 28.33 |
| Change | -0.86 |
If you invested $1000 in Tonix Pharmaceuticals Holding Corp. (TNXP) 10 years ago, it would be worth $0 as of September 16, 2025 at a share price of $27.75. Whereas If you bought $1000 worth of Tonix Pharmaceuticals Holding Corp. (TNXP) shares 5 years ago, it would be worth $0.05 as of September 16, 2025 at a share price of $27.75.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Tonix Pharmaceuticals Presents Clinical Data on Tonmya™ for the Treatment of Fibromyalgia at PAINWEEK 2025
GlobeNewswire Inc.
Sep 08, 2025 11:00 AM GMT
Tonmya was approved by FDA on August 15, 2025 for the treatment of fibromyalgia and is the first new FDA approved treatment for fibromyalgia in over 15 years Two pivotal Phase 3 studies demonstrated Tonmya significantly reduced fibromyalgia pain comp
Tonix Pharmaceuticals to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2025
GlobeNewswire Inc.
Aug 28, 2025 11:00 AM GMT
CHATHAM, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated biotechnology company with marketed products and a pipeline of development candidates, today announce
Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia
GlobeNewswire Inc.
Aug 15, 2025 7:44 PM GMT
Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years Fibromyalgia is a chronic pain condition that affects more than 10 million adults in the U.S. who are mostly women Two Pivotal Phase 3 studies demonstrated To